A study of risk factors for acquisition of Epstein-Barr virus and its subtypes

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 474-482

  Higgins, Craig D ^a   Swerdlow, Anthony J ^a   Macsweem, Karen F ^b   Harrison, Nadine ^b,c   Williams, Hilary ^b,d   McAulay, Karen ^b   Thomas, Ranjit ^b   Reid, Stuart ^b   Conacher, Margaret ^b   Britton, Kathryn ^b   Crawford, Dorothy H ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Primary Care Division   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD SAMPLING; CONDOM; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORAL CONTRACEPTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SIBLING; TROPICS; VIRUS TYPING;

ADOLESCENT; ADULT; AGE FACTORS; BLOOD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GEOGRAPHY; HERPESVIRUS 4, HUMAN; HUMANS; MALE; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 33846787176     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510854     Document Type: Article

References (41)

1. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356:461-73.
2. De-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274:756-61.
3. Niederman JC, McCollum RW, Henle G, et al. Infectious mononucleosis - clinical manifestations in relation to EB virus antibodies. JAMA 1968; 203:205-9.
4. Henle W, Henle G. The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin, Heidelberg, New York: Springer-Varlag, 1979:279-320.
5. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry 1998; 173:475-81.
6. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-32.
7. Pereira M, Blake, JM, Macrae AD. EB virus antibody at different ages. Brit Med J 1969; 4:526-7.
8. Crawford DH. Epstein-Barr virus. In: Zucherman AJ, Banatvala JE, Pattison JR, et al., eds. Principles and practice of clinical virology. 5th ed. London: John Wiley & Sons, 2004:123-46.
9. Dan R, Chang RS. A prospective study of primary Epstein-Barr virus infections among university students in Hong Kong. Am J Trop Med Hyg 1990; 42:380-5.
10. Hesse J, Ibsen KK, Krabbe S, Uldall P. Prevalence of antibodies to Epstein-Barr Virus (EBV) in childhood and adolescence in Denmark. Scand J Infect Dis 1983; 15:335-8.
11. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly H. Infectious mononucleosis at the United States Military Academy: a prospective study of a single class over four years. Yale J Biol Med 1974; 47:182-95.
12. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986; 2:1122-4.
13. Israele V, Shirley P, Sixbey JW. Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis 1991; 163:1341-3.
14. Näher H, Gissmann L, Freese UK, Petzoldt D, Helfrich S. Subclinical Epstein-Barr virus infection of both the male and female genital tract - indication for sexual transmission. J Invest Dermatol 1992; 98:791-3.
15. Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002; 186:731-6.
16. Dambaugh T, Wang F, Hennessy K, Woodland E, Rickinson A, Kieff E. Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol 1986; 59:453-62.
17. Sample J, Young L, Martin B, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084-92.
18. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995; 67:197-255.
19. van Baarle D, Hovenkamp E, Dukers NHTM, et al. High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. J Infect Dis 2000; 181:2045-9.
20. Luxton JC, Williams I, Weller I, Crawford DH. Epstein-Barr virus infection of HIV-seropositive individuals is transiently suppressed by high-dose acyclovir treatment. AIDS 1993; 7:1337-43.
21. Falk KI, Zou J-Z, Lucht E, Linde A, Ernberg I. Direct identification by PCR of EBV types and variants in clinical samples. J Med Virol 1997; 51:355-63.
22. Sculley TB, Apolloni A, Hurren L, Moss DJ, Cooper DA. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis 1990; 162:643-8.
23. Denis M, Haumont H, Bollen A. Vaccination against Epstein-Barr virus (EBV): report of phase II studies using recombinant viral glycoprotein gp350 in healthy adults [abstract 14.01]. In: Program and abstracts of the 11th Biennial Conference of the International Association for Research on Epstein-Barr Virus and Associated Diseases. Regensburg, Germany: 2004.
24. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bact 1966; 91:1248-56.
25. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11:499-520.
26. Brooks JM, Croom-Carter DSG, Leese AM, Tierney RJ, Habeshaw G, Rickinson AB. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains. J Virol 2000; 74:1801-9.
27. Hughes K. Odds ratios in cross-sectional studies. Int J Epidemiol 1995; 24:463-4, 468.
28. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3:21.
29. StatCorp. Stata statistical software: release 8.0. College Station, TX: Stata Corporation, 2003.
30. Niederman JC, Evans AS, Subrahmanyan L, McCollum RW. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med 1970; 282:361-5.
31. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971; 123:263-70.
32. Infectious mononucleosis and its relationship to EB virus antibody: a joint investigation by university health physicians and P.H.L.S. laboratories. Brit Med J 1971; 4:643-6.
33. Morris MC, Edmunds WJ. The changing epidemiology of infectious mononucleosis? J Infect 2002; 45:107-9.
34. Kafuko GW, Henderson BE, Kirya BG, Munube GMR. Epstein-Barr virus antibody levels in children from the West Nile district of Uganda. Lancet 1972; 1:706-9.
35. Biggar RJ, Gardiner C, Lennette ET, Collins WE, Nkrumah FK, Henle W. Malaria, sex, and place of residence as factors in antibody response to Epstein-Barr virus in Ghana, West Africa. Lancet 1981; 2:115-8.
36. Crowcroft NS, Vyse A, Brown DWG, Strachan DP. Epidemiology of Epstein-Barr virus infection in pre-adolescent children: application of a new salivary method in Edinburgh, Scotland. J Epidemiol Community Health 1998; 52:101-4.
37. Morris MC, Edmunds WJ, Hesketh LM, et al. Sero-epidemioloigical patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales. J Med Virol 2002; 67:522-7.
38. Lai PK, Mackay-Scollay EM, Alpers MP. Epidemiological studies of Epstein-Barr herpesvirus infection in western Australia. J Hyg (Lond) 1975; 74:329-37.
39. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
40. Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006; 43:276-82.
41. Rickinson AB, Young LS, Rowe M. Influence of Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus-transformed B cells. J Virol 1987; 61:1310-7.